Aktis Oncology Announces Presentation of the First Clinical Data Supporting Broad Development of their First in Class Nectin-4 Targeting Radiopharmaceutical AKY-1189

Aktis Oncology Announces Presentation of the First Clinical Data Supporting Broad Development of their First in Class Nectin-4 Targeting Radiopharmaceutical AKY-1189

BOSTONOct. 24, 2024 -- Aktis Oncology, a clinical-stage oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for large patient populations not addressed by existing platform technologies, today announced data presented on its potential first-in-class, Nectin-4 targeting mini-protein radiopharmaceutical, AKY-1189, in three abstracts, including one oral presentation, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, SpainOctober 23-25, 2024. AKY-1189 is designed to deliver actinium-225 to Nectin-4 expressing tumors, with potential applications in locally advanced or metastatic urothelial carcinoma (mUC) and other Nectin-4 expressing cancers, such as breast, lung, colorectal and cervical.

Aktis Oncology Announces $175 Million Oversubscribed Series B Financing to Further Advance its Proprietary Radiopharmaceutical Pipeline

BOSTON, Sept. 30, 2024 -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. The financing was led by RA Capital Management, and co-led by RTW Investments and Janus Henderson Investors. A select syndicate of additional new investors joined the financing, including funds and accounts advised by T. Rowe Price Associates, Inc., Avidity Partners, and an undisclosed life sciences-focused investment fund. All existing institutional investors participated, as well as existing strategic investors Bristol Myers Squibb, Eli Lilly and Company, and MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc.

Aktis Oncology enters into Strategic Collaboration with Lilly

BOSTON, Mass. – May 21, 2024 — Aktis Oncology, a biotechnology company discovering and developing novel targeted radiopharmaceuticals to treat a broad range of solid tumors, today announced a multi-target discovery collaboration agreement with Eli Lilly and Company to generate anticancer radiopharmaceuticals using Aktis Oncology’s novel miniprotein technology platform. The collaboration draws on Aktis’ proprietary radiopharmaceutical platform together with Lilly’s expertise in oncology drug development and commercialization, with the goal of developing first- in-class and differentiated therapeutics for a range of solid tumors.

Aktis Oncology Raises $84 Million to Advance Novel Targeted Alpha Radiopharmaceuticals

CAMBRIDGE, Mass., Aug. 25, 2022 -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced it has raised a Series A Extension financing of $84 million, bringing the total capital raised to date to $161 million. The extension included participation from new premier healthcare investors Cowen Healthcare Investments, MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc., ArrowMark Partners, Mirae Asset Venture Investment, Timefolio Capital (formerly known as NS Investment), Pappas Capital, and other undisclosed participants. All existing investors MPM Capital, Vida Ventures, EcoR1 Capital, Octagon Capital, TCG Crossover, Bristol Myers Squibb, and Novartis participated in the financing.